BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point By Danielle Golovin, Staff Writer David Ricks has become...
...of Pharmaceutical Research and chairman and president at Qilu’s U.S. Innovation Research Center.Ocular disease company Oyster Point Pharma Inc....
...was EVP and CSO at Akorn Inc. (NASDAQ:AKRX). Danielle Golovin Gilead Sciences Inc. Robert W. Baird Phagelux Inc. Chiesi Farmaceutici S.p.A. Oyster Point Pharma Inc. Sonoma...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...follow-on through the sale of 8.5 million shares at $18. On Friday, ocular disease play Oyster Point Pharma Inc....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Inc. (NASDAQ:RAPT) hired Rodney Young as CFO. Young was CFO at Cellerant Therapeutics Inc. (see "Oyster Point...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...from their $11 offering price. Companies pricing at the low end of their ranges included Oyster Point...
BioCentury | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

...Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and...
...market conditions (see “Weakness Adds to Skittishness for IPO Queue” ). On Thursday, ophthalmic company Oyster Point Pharma Inc....
...shares at $16, the low end of its proposed range of $16-$18. The deal valued Oyster Point...
BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

...in the U.S and China for suicidal bipolar depression candidate NRX-101. Oyster Point sets IPO range Oyster Point Pharma Inc....
...at $350.4 million. Elizabeth Eaton, Staff Writer and Paul Bonanos, Associate Editor Alexion Pharmaceuticals Inc. RAPT Therapeutics Inc. NeuroRx Inc. Oyster Point Pharma Inc....
BioCentury | Oct 4, 2019
Financial News

Oct. 4 Financial Quick Takes: Innovent raises $300M in Hong Kong's first biotech follow-on; plus Oyster Point, Heron, Molecular Assemblies and Geneoscopy

...chapter in 2018 after having gone public first in New York. Oyster Point seeking NASDAQ IPO Oyster Point Pharma Inc....
...or greater stake are New Enterprise Associates, Versant Ventures and Invus Opportunities; the latter co-led Oyster Point's...
...advanced adenomas by quantifying eukaryotic RNA isolated from epithelial cells in stool. Elizabeth S. Eaton Innovent Biologics Inc. Oyster Point Pharma Inc. Heron...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...IO translational innovation platform and experimental medicine at Merck KGaA (Xetra:MRK). Dry eye disease company Oyster Point Pharma Inc....
...oncology China unit. Jonathan Block, Associate Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...Bio Inc. and Pionyr Immunotherapeutics Inc. (see “Kronos Plays Pipeline Into $105M” ). Goyal named Oyster Point Pharma Inc....
BioCentury | Mar 2, 2019
Company News

Emerging company roundup: Anthos, Maze, Oyster Point

...those genes with drug therapies (see “Navigating Third Rock’s Maze” ). Earlier in the week, Oyster Point Pharma Inc....
...runway to take one of its dry eye disease candidates through an NDA submission (see “Oyster Point...
Items per page:
1 - 10 of 18
BioCentury | Dec 10, 2020
Management Tracks

Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

...Plus: management moves at Phagelux, Chiesi, Kanova and Oyster Point By Danielle Golovin, Staff Writer David Ricks has become...
...of Pharmaceutical Research and chairman and president at Qilu’s U.S. Innovation Research Center.Ocular disease company Oyster Point Pharma Inc....
...was EVP and CSO at Akorn Inc. (NASDAQ:AKRX). Danielle Golovin Gilead Sciences Inc. Robert W. Baird Phagelux Inc. Chiesi Farmaceutici S.p.A. Oyster Point Pharma Inc. Sonoma...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...follow-on through the sale of 8.5 million shares at $18. On Friday, ocular disease play Oyster Point Pharma Inc....
BioCentury | Dec 6, 2019
Company News

Management tracks: Cancer therapy pioneer Desmond-Hellmann leaving Gates Foundation; plus CStone, Janssen, Akcea, insitro and more

...Inc. (NASDAQ:RAPT) hired Rodney Young as CFO. Young was CFO at Cellerant Therapeutics Inc. (see "Oyster Point...
BioCentury | Nov 7, 2019
Financial News

More weakness among IPOs as Galera, Centogene limp into marketplace

...from their $11 offering price. Companies pricing at the low end of their ranges included Oyster Point...
BioCentury | Oct 31, 2019
Financial News

Oyster Point, RAPT post gains after pricing IPOs at low end of range

...Investors’ appetite for new biotech listings has shown signs of waning this fall, but Oyster Point and...
...market conditions (see “Weakness Adds to Skittishness for IPO Queue” ). On Thursday, ophthalmic company Oyster Point Pharma Inc....
...shares at $16, the low end of its proposed range of $16-$18. The deal valued Oyster Point...
BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

...in the U.S and China for suicidal bipolar depression candidate NRX-101. Oyster Point sets IPO range Oyster Point Pharma Inc....
...at $350.4 million. Elizabeth Eaton, Staff Writer and Paul Bonanos, Associate Editor Alexion Pharmaceuticals Inc. RAPT Therapeutics Inc. NeuroRx Inc. Oyster Point Pharma Inc....
BioCentury | Oct 4, 2019
Financial News

Oct. 4 Financial Quick Takes: Innovent raises $300M in Hong Kong's first biotech follow-on; plus Oyster Point, Heron, Molecular Assemblies and Geneoscopy

...chapter in 2018 after having gone public first in New York. Oyster Point seeking NASDAQ IPO Oyster Point Pharma Inc....
...or greater stake are New Enterprise Associates, Versant Ventures and Invus Opportunities; the latter co-led Oyster Point's...
...advanced adenomas by quantifying eukaryotic RNA isolated from epithelial cells in stool. Elizabeth S. Eaton Innovent Biologics Inc. Oyster Point Pharma Inc. Heron...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...IO translational innovation platform and experimental medicine at Merck KGaA (Xetra:MRK). Dry eye disease company Oyster Point Pharma Inc....
...oncology China unit. Jonathan Block, Associate Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo...
BioCentury | Aug 1, 2019
Financial News

Vida seeking bigger deals, cures with $600M fund

...Bio Inc. and Pionyr Immunotherapeutics Inc. (see “Kronos Plays Pipeline Into $105M” ). Goyal named Oyster Point Pharma Inc....
BioCentury | Mar 2, 2019
Company News

Emerging company roundup: Anthos, Maze, Oyster Point

...those genes with drug therapies (see “Navigating Third Rock’s Maze” ). Earlier in the week, Oyster Point Pharma Inc....
...runway to take one of its dry eye disease candidates through an NDA submission (see “Oyster Point...
Items per page:
1 - 10 of 18